Showing results (51-60 of 91) with videos related to
Sort By:
Pageof 10
Future Oncology (London, England)|February 6, 2025
FOLFIRINOX-3 plus bevacizumab (bFOLFIRINOX3) in chemo-refractory metastatic colorectal cancer: a multicenter phase II trialHélène Bellio, Nicolas Roussot, Aurélie Bertaut, et al.Gut|July 13, 2021
Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapiesPaul Oster, Laurie Vaillant, Erika Riva, et al.Annals of Surgical Oncology|January 15, 2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resectionFrancois Ghiringhelli, Damien Bichard, Samuel Limat, et al.Frontiers in Oncology|December 26, 2025
Cancer-associated fibroblasts and their prognostic role in colorectal cancer: review and meta-analysisSilvia Mihaela Ilie, Laurentia Gales, Ana Maria Musina, et al.Journal for Immunotherapy of Cancer|January 16, 2026
Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytesEmma Groetz, Sabrina Perrey, Alvaro Baeza Garcia, et al.International Journal of Cancer|July 30, 2016
Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological scoreMarine Jary, Thierry Lecomte, Olivier Bouché, et al.Journal of Geriatric Oncology|January 18, 2020
Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and FranceArielle Elkrief, Corentin Richard, Julie Malo, et al.Journal for Immunotherapy of Cancer|August 4, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung studyFrancois Ghiringhelli, Yaacov R Lawrence, Enriqueta Felip, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2026
The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal CancerMichael Cecchini, Sae-Won Han, Soohyeon Lee, et al.Lung Cancer (Amsterdam, Netherlands)|May 8, 2026
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancerByoung Chul Cho, Sun Min Lim, Sang Hoon Lee, et al.Pageof 10